

# Mutational analysis of the latency-associated nuclear antigen DNA-binding domain of Kaposi's sarcoma-associated herpesvirus reveals structural conservation among gammaherpesvirus origin-binding proteins

Soo-Jin Han,<sup>1</sup> Jianhong Hu,<sup>1</sup> Brian Pierce,<sup>2</sup> Zhiping Weng<sup>2,3</sup> and Rolf Renne<sup>1</sup>

Correspondence  
Rolf Renne  
rrenne@ufl.edu

<sup>1</sup>Department of Molecular Genetics and Microbiology and UF Shands Cancer Center, University of Florida, Gainesville, FL 32610-3633, USA

<sup>2</sup>Bioinformatics Program, Boston University, Boston, MA 02215, USA

<sup>3</sup>Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA

The latency-associated nuclear antigen (LANA) of Kaposi's sarcoma-associated herpesvirus functions as an origin-binding protein (OBP) and transcriptional regulator. LANA binds the terminal repeats via the C-terminal DNA-binding domain (DBD) to support latent DNA replication. To date, the structure of LANA has not been solved. Sequence alignments among OBPs of gammaherpesviruses have revealed that the C terminus of LANA is structurally related to EBNA1, the OBP of Epstein–Barr virus. Based on secondary structure predictions for LANA<sub>DBD</sub> and published structures of EBNA1<sub>DBD</sub>, this study used bioinformatics tools to model a putative structure for LANA<sub>DBD</sub> bound to DNA. To validate the predicted model, 38 mutants targeting the most conserved motifs, namely three  $\alpha$ -helices and a conserved proline loop, were constructed and functionally tested. In agreement with data for EBNA1, residues in helices 1 and 2 mainly contributed to sequence-specific DNA binding and replication activity, whilst mutations in helix 3 affected replication activity and multimer formation. Additionally, several mutants were isolated with discordant phenotypes, which may aid further studies into LANA function. In summary, these data suggest that the secondary and tertiary structures of LANA and EBNA1 DBDs are conserved and are critical for (i) sequence-specific DNA binding, (ii) multimer formation, (iii) LANA-dependent transcriptional repression, and (iv) DNA replication.

Received 11 February 2010  
Accepted 17 May 2010

## INTRODUCTION

Kaposi's sarcoma-associated herpesvirus (KSHV; human herpesvirus 8) is a DNA tumour virus associated with Kaposi's sarcoma, primary effusion lymphomas and a plasmablastic variety of multicentric Castleman's disease (Cesarman *et al.*, 1995; Chang *et al.*, 1994; Soulier *et al.*, 1995). The latency-associated nuclear antigen (LANA), encoded by ORF73, interacts with multiple cellular proteins to affect various signal transduction pathways (Gao *et al.*, 1996; Kedes *et al.*, 1996). LANA also functions as an origin-binding protein (OBP) by binding to the viral latent origin, and recruits the host cellular replication machinery to ensure replication of viral episomes during S phase. Additionally, LANA tethers viral genomes to mitotic chromosomes via its N-terminal chromosome-binding motif, thereby contributing

to episomal maintenance (Ballestas & Kaye, 2001; Ballestas *et al.*, 1999; Barbera *et al.*, 2006; Cotter & Robertson, 1999; Garber *et al.*, 2002; Hu *et al.*, 2002; You *et al.*, 2006).

The C-terminal LANA DNA-binding domain (LANA<sub>DBD</sub>, aa 775–1003; Garber *et al.*, 2001) binds cooperatively to LANA binding sites 1 and 2 (LBS1/2) within viral terminal repeats (TRs) for replication of TR-containing plasmids (Garber *et al.*, 2001, 2002; Hu *et al.*, 2002). LANA predominantly forms dimers, and the dimerization domain has been mapped to the LANA<sub>DBD</sub> (Schwam *et al.*, 2000), which also has partial replication activity (Hu *et al.*, 2002). LANA and EBNA1, the OBP of Epstein–Barr virus (EBV), are functional homologues with respect to DNA binding and supporting DNA replication by recruitment of cellular origin recognition complex proteins. Both proteins form dimers in solution and bind to two sites within their respective origins of replication in a cooperative manner (Lim *et al.*, 2002; Schepers *et al.*, 2001; Stedman *et al.*, 2004; Verma *et al.*, 2006).

A supplementary figure and table are available with the online version of this paper.

Neither the structure of full-length LANA nor its DNA-binding domain (DBD) has been determined to date. In contrast, crystal structures of EBNA1 in the presence and absence of DNA (Bochkarev *et al.*, 1995, 1996) and E2, the OBP of human papillomavirus (HPV) (Hegde *et al.*, 1992), have been solved. Although EBNA1 and E2 share very limited primary sequence homology and are encoded by different classes of DNA tumour virus, their DBDs revealed a common core domain structure. The core domain consists of a series of interspersed  $\beta$ -sheets, which form a  $\beta$ -barrel within the dimer interface, a proline loop, which interacts with cellular proteins, and three  $\alpha$ -helices, which make direct or indirect contacts to DNA and stabilize higher-order multimers (Bochkarev *et al.*, 1995, 1996; Ceccarelli & Frappier, 2000). To gain insights into the possible structure of the LANA<sub>DBD</sub> in the absence of a crystal structure, we performed detailed sequence alignments among the LANA<sub>DBD</sub>s of different rhadinoviruses and performed bioinformatics-based modelling to predict a potential structure. We investigated our model by mutational analysis and by functional testing of mutants targeting residues most conserved between different LANA<sub>DBD</sub>s and EBNA1<sub>DBD</sub>.

## RESULTS

### High evolutionary conservation of LANA<sub>DBD</sub>s in gammaherpesviruses and bioinformatics-based predicted structure of KSHV LANA<sub>DBD</sub>

Grundhoff & Ganem (2003) first noted a limited secondary structure homology between the C termini of LANA and EBNA1. Furthermore, sequencing LANA from a retro-peritoneal fibromatosis-associated herpesvirus variant from *Macaca nemestrina* (RFHVMn) and *Macaca nemestrina* rhadinovirus 2 (MneRV2) revealed that the C-terminal amino acids of their LANAs showed the strongest sequence conservation (Burnside *et al.*, 2006). To analyse these homologies further, we performed amino acid alignment among the LANA<sub>DBD</sub>s of KSHV, RFHVMn and rhesus monkey rhadinovirus (RRV) and the EBV EBNA1<sub>DBD</sub> using the bioinformatics programs PRALINE, 3D-PSSM and T-Coffee (Fig. 1 and Table 1). This analysis revealed that KSHV LANA<sub>DBD</sub> had greater than 50% similarity to the DBDs of RFHVMn and RRV. Although EBNA1<sub>DBD</sub> had less than 16% overall amino acid sequence identity to LANA<sub>DBD</sub>s (Table 1), there was significant structural similarity such as the presence of three  $\alpha$ -helices, as noted previously (Grundhoff & Ganem, 2003). In addition, we found a proline-rich loop motif that was conserved between KSHV LANA<sub>DBD</sub> (<sup>930</sup>PHPGPDQSP<sup>938</sup>) and EBV EBNA1<sub>DBD</sub> (<sup>545</sup>PGPGPQPGP<sup>553</sup>) (Fig. 1b), which is important for the protein–protein interactions of EBNA1 (Bochkarev *et al.*, 1996). We also noted that, among KSHV, RFHVMn and RRV, residues within the  $\alpha$ -helices were more highly conserved than the surrounding residues (Fig. 1a). Based on these observations, we performed bioinformatics

modelling to predict the KSHV LANA<sub>DBD</sub> structure, a common approach for related proteins for which crystals cannot easily be obtained (Hantz *et al.*, 2009; Hass *et al.*, 2008; Purta *et al.*, 2005).

KSHV LANA<sub>DBD</sub> residues 868–960 were modelled with the 3D-JIGSAW modelling tool (Bates *et al.*, 2001) using the EBNA1<sub>DBD</sub> structure (PDB accession no. 1B3T) as template (Bochkarev *et al.*, 1996). The LANA<sub>DBD</sub> residues 929–939 did not have defined coordinates after 3D-JIGSAW analysis and were modelled using ModLoop (Fiser & Sali, 2003). Despite the relatively low residue homology, the structure for a LANA<sub>DBD</sub> monomer was very similar to chain A of EBNA1<sub>DBD</sub>. The root mean square deviation (RMSD) was 0.85 Å between the EBNA1<sub>DBD</sub> structure and the predicted LANA<sub>DBD</sub> model, suggesting close similarity.

To predict the multimer structure of LANA<sub>DBD</sub>, the program M-ZDOCK (Pierce *et al.*, 2005) was run using the LANA<sub>DBD</sub> homology model to perform a full search of possible homodimeric interfaces. The output models from M-ZDOCK were then filtered based on similarity to the EBNA1<sub>DBD</sub> dimer interfaces, the ability to fit double-stranded DNA and the score of the model from the program ZRANK (Pierce *et al.*, 2007). We next selected two M-ZDOCK models for the LANA<sub>DBD</sub> dimer using these criteria, which were joined to construct a tetramer (Fig. 2a). The RMSD for the LANA<sub>DBD</sub> dimer versus the two EBNA1<sub>DBD</sub> chains was 2 Å.

We have shown previously that LANA binds to LBS1/2 within the TRs, which are spaced by 21–22 nt (Garber *et al.*, 2002), and Wong & Wilson (2005) demonstrated that LANA occupying both sites induces a bend of about 110°. Whilst the sequence composition between EBNA1-binding sites (AT-rich) and LANA-binding sites (GC-rich) is very different, both the spacing and the induced DNA bending are conserved features. Accordingly, the DNA conformation was initially taken from the structure of EBNA1<sub>DBD</sub> bound to DNA (Bochkarev *et al.*, 1996) and fitted to the two dimers in the LANA<sub>DBD</sub> tetramer. The linking DNA between the two dimer-binding sites was extended from the existing DNA strands. The Rosetta program (Havranek *et al.*, 2004) was then used to restore the DNA sequence to the LBS1/2 sequences and repack the LANA side chains accordingly.

The resulting model for the LANA<sub>DBD</sub> tetramer bound to DNA (Fig. 2a) shared the defining  $\beta$ -barrel core domain structure with both EBNA1<sub>DBD</sub> and E2<sub>DBD</sub>. The dimer of LANA<sub>DBD</sub> was composed of eight antiparallel  $\beta$ -strands within their core domains, and flanking domains including helices 1 (Fig. 2a in red) (Bochkarev *et al.*, 1995), which were positioned at the outside of each monomer towards the dimer interfaces. The  $\beta$ -barrel formation was composed of four  $\beta$ -strands from each monomer, and the  $\beta$ -strands were connected by crossover of the two  $\alpha$ -helices (within each core domain) (Fig. 2a in blue and green) on the outside of each barrel. Hence, our model incorporated all known data on the LANA<sub>DBD</sub>–DNA interaction (Garber *et al.*, 2002; Wong & Wilson, 2005), and suggested similar secondary and quaternary structures for LANA<sub>DBD</sub> and EBNA1<sub>DBD</sub>.



**Table 1.** Similarity and identity of the C termini among gammaherpesvirus OBPs


	Amino acid similarity (identity) (%)			
	KSHV	RRV	RFHVMn	EBV
KSHV	100	–	–	–
RRV	53 (30)	100	–	–
RFHVMn	54 (40)	46 (26)	100	–
EBV	53 (14)	43 (16)	30 (13)	100

CV-1 cells as described previously (Garber *et al.*, 2001, 2002). Briefly, constructs containing T7 promoter were transfected into MVA/T7-infected cells. The cells were harvested 36 h post-transfection and the proteins were enriched by affinity purification. Expression levels for all


mutant proteins were monitored by Western blotting (see Supplementary Fig. S1, available in JGV Online).

### Evaluation of wt and mutant KSHV LANA<sub>DBD</sub>s for DNA binding by electrophoretic mobility shift assay (EMSA)

We reported previously that LANA<sub>DBD</sub> binds to its high-affinity binding site (LBS1) with a  $K_d$  of  $1.51 \pm 0.16$  nM (Garber *et al.*, 2002). To determine the effect of mutations on DNA binding, equal amounts of wt and mutant LANA<sub>DBD</sub> proteins were incubated with radiolabelled probes containing either LBS1 or LBS1/2 (Fig. 3). After electrophoresis, the gels were dried and signals were quantified by phosphoimaging. Representative autoradiographs from three independent experiments are shown.



**Fig. 2.** Computational model of the LANA<sub>DBD</sub> and multimer structure bound to DNA. The figure shows the LANA<sub>DBD</sub> model with the specific DNA-binding site predicted by the M-ZDOCK program based on alignment with the structure of EBNA1<sub>DBD</sub>. (a) The tetramer formed by combining two dimers bound to their respective LBS1/2 (DNA helix in light blue and green). The  $\beta$ -barrel bundle is made of four  $\beta$ -strands from each monomer at the dimer interface. (b) Each monomer is composed of four  $\beta$ -strands and three helices (helix 1 in red, helix 2 in blue and helix 3 in green). (c, d) Crucial amino acids for DNA contact or dimerization are shown in yellow: <sup>871</sup>K and <sup>875</sup>Q for helix 1, <sup>963</sup>W and <sup>964</sup>E for helix 3 (c) and <sup>907</sup>Y, <sup>910</sup>K and <sup>911</sup>K for helix 2 (d). The monomer pictures were generated using ViewerLite 4.2 (Accelrys).



**Fig. 3.** DNA-binding activity of LANA<sub>DBD</sub> mutants. Purified LANA<sub>DBD</sub> wt and mutant proteins were incubated with radiolabelled LBS1 or LBS1/2 as described previously (Garber *et al.*, 2001). The DNA-binding affinity is represented as the percentage for mutants compared with wt LANA<sub>DBD</sub>, which was set to 100%. In each assay, all mutants were tested for DNA-binding activity with LBS1 (a–c) or LBS1/2 (d). EMSA results are shown for helix 1 mutants (a), helix 2 mutants (b), helix 3 mutants (c) and adapted mutants from each helix (d). Arrows indicate specific protein–DNA complexes. NC, Probe alone as a negative control; wt, wt LANA<sub>DBD</sub>. Results on graphs are shown as means ± SD from three independent experiments.

Most mutants in helix 1 significantly reduced the binding affinity to both LBS1 and LBS1/2 (Fig. 3a, d). In particular, P874A and H876A reduced the DNA-binding affinity to less than 20% of that of wt (Fig. 3a, lanes 5 and 8). Helix 1 (<sup>871</sup>K–<sup>882</sup>F) contains the polar residues <sup>871</sup>K, <sup>873</sup>R and <sup>879</sup>Y, which are highly conserved residues among KSHV, RFHVMn and RRV (Fig. 1a). These residues potentially contact DNA either directly or indirectly by stabilizing the secondary structure of the N-terminal domain of LANA<sub>DBD</sub>. From the structure of EBNA1<sub>DBD</sub>, polar residue <sup>477</sup>K within helix 1 and residues <sup>461</sup>K–<sup>469</sup>R within the N terminus have been shown to contact DNA directly (Bochkarev *et al.*, 1996). In agreement with the binding data, the predicted structure (Fig. 2) suggested that the N-terminal residues of helix 1 (<sup>871</sup>K, <sup>873</sup>R and <sup>875</sup>Q) are located in close approximation to the DNA (Fig. 2b, c). For EBNA1<sub>DBD</sub>, residues within helix 2, which was originally termed the DNA recognition helix (Bochkarev *et al.*, 1995), also contribute to DNA binding. The recognition helices of all HPV E2 proteins contain several highly conserved residues in a consensus motif (<sup>338</sup>LXXLR<sup>343</sup>), which is also conserved in EBNA1<sub>DBD</sub> (<sup>517</sup>LYNLR<sup>522</sup>) (Fujita *et al.*, 2001). Within LANA<sub>DBD</sub>, <sup>906</sup>PYGLKK<sup>911</sup> in helix 2 has a similar surface charge to EBNA1<sub>DBD</sub> helix 2 (Fig. 1). Moreover, in the model, <sup>907</sup>Y and <sup>910</sup>KK<sup>911</sup>, like <sup>518</sup>Y and <sup>521</sup>RR<sup>522</sup> of EBNA1<sub>DBD</sub>, were predicted to be in close contact with the DNA (Fig. 2d). Indeed, all mutants in helix 2, except L909A, showed dramatically reduced DNA-binding affinities to both LBS1 and LBS1/2 (Fig. 3b, d).

For EBNA1<sub>DBD</sub>, it was shown that the proline loop (<sup>545</sup>PGPGPQPGP<sup>553</sup>) between helix 2 and the  $\beta$ -barrel bundle contributes to DNA binding as well as to protein–protein interactions with cellular transcription factors (Bochkarev *et al.*, 1995, 1996). Mutant P932A in the centre of the proline loop (<sup>930</sup>PHPGPDQSP<sup>938</sup>) of LANA<sub>DBD</sub> did not reduce DNA-binding affinity (Fig. 3b, lane 13); however, P925A located inside the  $\beta$ -barrel bundle reduced binding affinity by about 50% (Fig. 3b, lane 12).

Helix 3 (<sup>950</sup>K–<sup>966</sup>S) followed the proline loop and continued towards the inside of the  $\beta$ -barrel through an extended strand. In contrast to mutants in helices 1 and 2, helix 3 mutants, except for SKK953AAA, L961A, W963A and WE963AA, did not show significant changes in DNA-binding affinity (Fig. 3c, d and Table 2). SKK953AAA in helix 3 may change folding by interrupting hydrogen bonds with basic residues of helix 1. Thus, these helix 3 residues contribute towards stabilizing protein–DNA interactions and, in contrast to residues within helices 1 and 2, are not directly involved in DNA binding.

### Evaluation of multimerization of KSHV LANA<sub>DBD</sub> by co-immunoprecipitation assays

Schwam *et al.* (2000) first demonstrated that LANA<sub>DBD</sub> in solution and in the absence of TR DNA exists predominantly as a homodimer. To analyse dimerization of a subset of mutants with reduced DNA-binding activities, we

performed co-immunoprecipitation assays. Flag-tagged wt or mutant LANA<sub>DBD</sub>s were tested for their ability to interact with haemagglutinin (HA)-tagged wt LANA<sub>DBD</sub>. LANA<sub>DBD</sub> complexes were immunoprecipitated by anti-Flag beads and separated by SDS-PAGE. The amount of wt LANA<sub>DBD</sub> precipitated was detected and quantified by Western blotting using anti-HA antibody. The dimerization activity for each mutant is reported as the percentage relative to that of HA- and Flag-tagged wt LANA<sub>DBD</sub>, which was set to 100%.

Mutants HIF876AAA and YR879AA in helix 1, which showed drastically reduced DNA-binding affinities, did dimerize at a level comparable to wt (Fig. 4a, lanes 5–8). RF881AA and Q875A reduced dimerization only (Fig. 4b, lanes 5 and 6, and Table 2), further suggesting that most helix 1 residues contribute directly to DNA binding but not to dimer formation.

Similarly, except for YGL907AAA, which showed a moderate decrease (73%) in dimerization (Fig. 4b, lanes 7 and 8), helix 2 mutants had largely unaltered or increased dimerization activities compared with wt (Fig. 4c, lanes 5–8). This result was expected, as helix 2 of EBNA1<sub>DBD</sub> and presumably LANA<sub>DBD</sub> function as a DNA recognition domain. In addition, P925A within the  $\beta$ -barrel connected to the proline loop did not affect dimerization (Table 2).

Within helix 3, several mutants had reduced dimerization (Fig. 4d–f). Dimerization for WE963AA and SKK953AAA was reduced to 29 and 64%, respectively (Fig. 4f, lanes 7 and 8, and Table 2). Within the EBNA1<sub>DBD</sub>, the corresponding mutants in helix 3 showed the loss of both dimerization and DNA replication activities (Bochkarev *et al.*, 1996).

### Analysis of DNA replication activity of wt and mutant KSHV LANA<sub>DBD</sub>s

Mutagenesis of the LBS1/2 showed that the replication efficiency of TR-containing plasmids is dependent on the LBS1 (Garber *et al.*, 2002). To test the inverse, we chose a subset of mutants with reduced DNA binding or dimerization and performed transient replication assays as described previously (Garber *et al.*, 2002; Hu *et al.*, 2002). Briefly, a plasmid containing four copies of the TR was co-transfected with plasmid expressing wt or mutant LANA<sub>DBD</sub> into 293 cells. Replicating DNA was extracted and analysed by Southern blotting after *DpnI* digestion. As described previously, LANA<sub>DBD</sub> replicated with about 20% efficiency compared with full-length LANA (compare Fig. 5a, lanes 9–11, and Fig. 5b, lanes 7–9) (Hu *et al.*, 2002).

The mutants with reduced binding affinity in helix 1 (HIF876AAA and YR879AA), helix 2 (YGL907AAA, KK910AA and LSQ912AAA) and helix 3 (SKK953AAA) did not replicate to detectable levels (Fig. 5a, lanes 12–15, and b, lanes 10 and 11). Furthermore, WE963AA in helix 3, which strongly reduced dimerization, was also inactive in

**Table 2.** Summary of LANA<sub>DBD</sub> mutants and their relative activities in DNA binding, dimerization, replication and transcription repression

NT, Not tested.

Position	Mutant	EMSA*		IP†	RA‡	Repression assay§
		LBS1	LBS1/2			
Helix 1	K871A	74 (±4.8)	35 (±2.2)	74	NT	79 (±8)
	R873A	48 (±2.9)	18 (±1.6)	135	NT	103 (±12)
	P874A	19 (±1.3)	21 (±2.1)	98	NT	77 (±13)
	Q875A	40 (±2.5)	8 (±2.02)	57	NT	87 (±11)
	HIF876AAA	28 (±1.9)	3 (±1.85)	127	–	41 (±7)
	H876A	14 (±1.6)	NT	NT	NT	66 (±5)
	I877A	21 (±2.4)	NT	NT	NT	65 (±6)
	F878A	32 (±1.8)	NT	NT	NT	–
	YR879AA	26 (±1.5)	5 (±2.11)	73	–	67 (±8)
	Y879A	29 (±2.2)	NT	NT	NT	75 (±4)
	R880A	55 (±3.4)	NT	NT	NT	7.4 (±0.6)
	RF881AA	61 (±3.5)	15 (±2.54)	31	NT	NT
	R881A	64 (±3.6)	NT	NT	NT	NT
	F882A	48 (±2.6)	NT	NT	NT	NT
Helix 2	YGL907AAA	23 (±7.8)	25 (±3.01)	73	–	–
	Y907A	10 (±2.8)	NT	NT	NT	71 (±6)
	L909A	74 (±0)	NT	NT	NT	NT
	KK910AA	34 (±2.1)	5 (±2.29)	210	–	NT
	K910A	21 (±6.5)	NT	NT	NT	NT
	K911A	11 (±2.8)	NT	NT	NT	NT
	LSQ912AAA	28 (±3.6)	19 (±2.97)	248	–	50 (±3)
	F916A	52 (±2.1)	NT	NT	NT	NT
	Q917A	32 (±6.3)	NT	NT	NT	NT
	P925A	51 (±3.5)	20 (±2.3)	200	NT	72 (±7)
Proline loop	P932A	99 (±2.1)	NT	NT	NT	83 (±6)
Helix 3	KDT950AAA	112 (±16)	NT	74	NT	93 (±9)
	SKK953AAA	33 (±18)	54 (±3.82)	64	NT	65 (±11)
	VQM956AAA	71 (±13)	77 (±4.1)	88	NT	NT
	V956A	108 (±9)	NT	NT	NT	NT
	Q957A	138 (±13)	NT	147	NT	86 (±5)
	M958A	146 (±18)	NT	–	NT	94 (±2)
	RL960AA	97 (±14)	91 (±3.87)	104	NT	NT
	R960A	106 (±11)	NT	NT	NT	NT
	L961A	59 (±7.8)	NT	NT	NT	69 (±6)
	WE963AA	65 (±11.5)	56 (±3.33)	29	–	0.2 (±4)
W963A	70 (±12)	NT	NT	NT	64 (±4)	
E964A	104 (±9.1)	NT	NT	NT	94 (±7)	
S966A	136 (±16)	127 (±4.6)	188	+/-	82 (±13)	

\*Detection levels by EMSA in the presence of a single or double DNA-binding site. Numbers indicate the percentage of relative binding affinity compared with that of wt.


†IP, Detection levels by immunoprecipitation. Numbers indicate the percentage of dimerization activity compared with that of wt.

‡RA, Replication activity. –, No activity; +/-, reduced activity compared with that of LANA<sub>DBD</sub>.

§Transcription repression activity. Numbers indicate the percentage of transcriptional repression activity compared with that of wt.

the replication assay (Fig. 5b, lane 12). In contrast, S966A, which had no phenotype in either binding or dimerization, showed residual replication activity (Fig. 5a, lane 16). These data further confirmed that LANA dimerization and high-affinity binding to the TR are required for replication. Interestingly, whilst the proline loop mutant P932A bound

to DNA and dimerized like the wt, it did not support replication (Table 2 and data not shown). For EBNA1<sub>DBD</sub>, it has been shown that the proline loop contributes to spatial orientation of helices 1 and 2 and interacts with cellular proteins (Bochkarev *et al.*, 1995, 1996; Ceccarelli & Frappier, 2000).



**Fig. 4.** Co-immunoprecipitation assays with alanine substitution mutants. The dimerization ability of Flag-tagged wt or mutant LANA<sub>DBD</sub>s with HA-tagged wt LANA<sub>DBD</sub> was tested. Dimerization activity for each mutant was normalized based on the expression level of Flag-tagged wt or mutant LANA<sub>DBD</sub> proteins. L, Cell lysate, IP; immunoprecipitated samples; Wt (N), HA-tagged wt only as a negative control; Wt (P), Flag-tagged and HA-tagged wt as a positive control.


**Transcriptional repressor activity of wt and mutant LANA<sub>DBD</sub>s**

We and others have previously shown that the TR sequences have enhancer activity, which can be repressed by LANA. Furthermore, LANA<sub>DBD</sub> alone is sufficient for repression (Garber *et al.*, 2001). To test mutants for repressor activity, plasmids encoding wt or mutant LANA<sub>DBD</sub> were co-transfected with pGL3/7TR reporter plasmid into 293 cells. Cell lysates were assayed for luciferase activity and normalized as described previously (Renne *et al.*, 2001). The data for mutants in all three helices is shown as the percentage repression activity compared with that of wt, which was set to 100% (Fig. 6).

Within helix 1, eight out of 11 mutants had only moderately decreased repression activity of between 80 and 65% compared with wt. Repression activity of HIF876AAA and F878A was decreased to 41% and to less than 1% of wt, which was concordant with strongly reduced binding activity (Fig. 6a and Table 2). Interestingly, R880A showed only 7% repression activity despite its DNA binding activity only being reduced to 55% (Fig. 6a and Table 2).


Within helix 2, four out of five tested mutants showed significantly decreased repression activity, the exception being Y907A. These were mostly concordant with either loss of or a strong reduction in DNA binding (Table 2). These data further confirmed that residues in helix 2 significantly contribute to DNA recognition and binding. Interestingly, the DNA binding of Y907A was strongly reduced, although it displayed 71% repressor activity (Fig. 6b).

In agreement with the DNA-binding data, most mutants in helix 3, including the proline loop, had a modest or no



**Fig. 5.** Analysis of DNA replication mediated by alanine substitution mutants using a short-term replication assay. LANA<sub>DBD</sub>-expressing constructs were co-transfected with pPuro/4TR into 293 cells; 10% of the extracted DNA (Hirt, 1967) was digested with *Hind*III as input (a, lanes 1–8, and b, lanes 1–6) and the remaining DNA was double digested with *Hind*III and *Dpn*I (a, lanes 9–16, and b, lanes 7–12). The DNA was detected by Southern blotting with a radiolabelled 4TR probe. Full-length LANA was transfected as a positive control. The arrow indicates the position of full-length pPuro-4TR.





**Fig. 6.** Analysis of the activity of LANA-dependent transcriptional repression by alanine substitution. Graphical representation of data from luciferase reporter assays. pGL3/7TR luciferase reporter and wt or mutant LANA<sub>DBD</sub> plasmid were co-transfected. RLU values were normalized to total protein concentration as described previously (Renne *et al.*, 2001). The percentage of suppression activity was compared with that of LANA<sub>DBD</sub> wt, which was set to 100%. Results are shown as means  $\pm$  SD from three independent experiments. (-)LANA, Negative control with no LANA<sub>DBD</sub>.

effect on transcriptional repression (Fig. 6b, c). However, WE963AA completely abolished repressor activity. Interestingly, although WE963AA had only modestly reduced DNA-binding activity (Table 2), it had strongly reduced homodimer formation, suggesting that these residues may interact with helix 1 to stabilize the

homodimer or contribute to interactions with cellular proteins conveying transcriptional repression.

In summary, these data showed that, for most of the mutants, DNA binding and transcriptional repression were similarly affected. However, we observed some mutants, notably R880A and WE963AA, that could bind to the TR but did not repress transcription, and one mutant, Y907A, that bound poorly to the TR but still repressed transcription.

## DISCUSSION

Many mechanistic details on the role of LANA in transcriptional regulation, latent DNA replication, tethering of viral episomes to host chromatin and interaction with multiple host cellular proteins have been reported (reviewed by Lieberman *et al.*, 2007; Verma *et al.*, 2007). In contrast, with the exception of a small 23 aa peptide in the N-terminal histone H2A-binding domain (Barbera *et al.*, 2006), no structural data is available on LANA. We have expressed LANA<sub>DBD</sub> protein using vaccinia virus, baculovirus and *Escherichia coli* systems, but have not yielded concentrations of soluble protein amenable to crystallization. A further complicating factor is that all published DNA-binding assays have been performed in the presence of BSA, substitution for which will be crucial to solve the LANA<sub>DBD</sub> structure in the presence of its cognate binding site (Ballestas & Kaye, 2001; Cotter & Robertson, 1999; Garber *et al.*, 2002).

In the meantime, we performed bioinformatics modelling based on the observed sequence homology between the DBDs of KSHV, RRV and RFHVMn LANA and the DBD of EBNA1 to predict a structure for KSHV LANA<sub>DBD</sub>. We note that the X-ray structures of the EBNA1<sub>DBD</sub> and E2<sub>DBD</sub> core domains, which show no discernible sequence homology, superimpose almost perfectly (Bochkarev *et al.*, 1996; reviewed by Grossman & Laimins, 1996; Hegde *et al.*, 1992; Liang *et al.*, 1996). In contrast, the DBDs of LANA and EBNA1 showed 14% identity and 53% similarity (Table 1) and the highest conservation was within motifs that are crucial for the overall core domain structure (Fig. 1b) (Grundhoff & Ganem, 2003). As a result, the predicted model (Fig. 2) indicated a high degree of structural relatedness.

To functionally validate this model, we targeted the three  $\alpha$ -helices and the proline loop, which showed the highest conservation (Fig. 1b) and for which phenotypes have been described for EBNA1<sub>DBD</sub>. We identified residues in all three  $\alpha$ -helices that are crucial for DNA binding (helices 1 and 2) or multimerization (helix 3). Both efficient DNA binding and dimerization are crucial for LANA's ability to support replication of the TR-containing plasmids. The functional data for all mutants is summarized in Table 2. The key observations were that charged residues within a conserved motif in helix 2 (<sup>906</sup>PYGLKK<sup>911</sup>) were crucial for DNA binding (Fig. 2d). Helix 1 of LANA<sub>DBD</sub> also contributed to binding, presumably through direct interactions with DNA

(Fig. 3a, d). These data are in agreement with those for EBNA1<sub>DBD</sub> where helices 1 and 2 both significantly contribute to DNA binding. Interestingly, within the crystal structure, helix 1 of EBNA1<sub>DBD</sub> was located much closer to the DNA than helix 2. However, biochemical data by Cruickshank *et al.* (2000) clearly demonstrated that helix 2 is also critical for DNA binding. To explain the difference between the crystal structure of EBNA1<sub>DBD</sub> bound to DNA and the biochemical data, it was suggested that EBNA1 binds to DNA via a two-step mechanism: sequence-specific binding is initiated by helix 2 followed by interactions of helix 1 residues. The observation that LANA residues from both helices contribute to binding activity points to a conserved DNA-binding mechanism for EBNA1 and the rhadinovirus LANA proteins, which has also been suggested for the HPV E2 protein (reviewed by de Prat-Gay *et al.*, 2008; Hegde *et al.*, 1992; Liang *et al.*, 1996).

Most mutations in helices 1 and 2 reduced transcriptional repressor activity as well as reducing DNA binding (Table 2). These data are consistent with the previous observation that high and low affinities of LBS1/2 determine DNA binding and replication (Garber *et al.*, 2002). In contrast, most mutants in helix 3 had only moderate effects on transcriptional suppression; however, mutant WE963AA displayed greatly reduced repression but only moderately reduced DNA binding (Fig. 3c and Table 2), indicating a role in protein–protein interactions that conveys LANA-dependent repression.

These data strongly suggest functional homology between all three  $\alpha$ -helices and the proline loop of KSHV LANA<sub>DBD</sub> and EBNA1<sub>DBD</sub>. In addition, this analysis yielded at least one mutant in each helix and in the proline loop that showed discordance in phenotype with regard to DNA binding, homodimer formation, transcriptional repression or DNA replication. Within helix 1, R880A bound to the TR but had almost no repressor activity. Conversely, Y907A in helix 2 significantly reduced DNA binding but still repressed transcription, and WE963AA in helix 3 had only moderately reduced binding but completely lost repression activity. Finally, proline loop mutant P932A had no defect in either binding or dimerization, but did not support DNA replication. These mutants will be useful for further mechanistic studies on LANA function and some may function as dominant-negative proteins, which have not been described to date for LANA.

Previously, two studies have performed mutational analysis of the LANA C-terminal domain. First, Wong & Wilson (2005) introduced a limited set of mutations and analysed their effect on DNA binding and found that binding to DNA induced 57° bending or greater for LBS1 and about 110° for occupation on LBS1/2; furthermore, mutations preventing bending also greatly affected DNA binding of LANA. We observed similar results for mutants SKK953AAA and WE963AA in helix 3, confirming that changes in DNA bending do contribute to decreased DNA binding and replication activity (Wong & Wilson, 2005). Additionally,

Kelley-Clarke *et al.* (2007) performed an unbiased mutational analysis across LANA<sub>DBD</sub> by introducing triple alanine substitutions to define residues important for binding to the TR and attachment to host chromatin.

With respect to the importance of helix 2 for DNA recognition, our data are in agreement with both previous studies and add further details by identifying several residues whose mutation alone eliminates DNA binding. In particular, <sup>909</sup>L, <sup>910</sup>K, <sup>911</sup>K and <sup>917</sup>Q partly overlap with the conserved LXXLRY motif present in the core domains of EBNA1 and many HPV E2 proteins (Fujita *et al.*, 2001).

With respect to helices 1 and 3, we identified several residues that contribute to DNA binding but were not identified previously (Kelley-Clarke *et al.*, 2007). Specifically, HIF876AAA, YR879AA and all corresponding single amino acid substitutions showed drastically reduced DNA binding (Figs 3 and 4 and Table 2). In agreement with our observation, the corresponding EBNA1<sub>DBD</sub> residues are also important for DNA binding and bending, either by contacting the DNA directly or by stabilizing the N-terminal domain of DBD (Bochkarev *et al.*, 1996). No significant changes in DNA binding were observed within helix 3 mutants. However, RL960AA, which was previously shown not to bind to DNA (Kelley-Clarke *et al.*, 2007), bound to LBS1 or LBS1/2 with wt activity levels (Fig. 4) and also formed dimers. Observed differences between the two studies may in part be due to differences in protein expression and purification method utilized.

In summary, our data suggest that LANA<sub>DBD</sub> has a high degree of structural conservation with EBNA1<sub>DBD</sub>, which is critical for sequence-specific DNA binding, multimer formation, protein–protein interactions required for its DNA replication activity and LANA-dependent transcriptional repression.

## METHODS

**Amino acid alignment of gammaherpesviruses LANA<sub>DBD</sub>s of different primate species and EBNA1.** The sequences of KSHV LANA<sub>DBD</sub> (aa 775–1003; NCBI Protein accession no. AAK50002), the reference BC-1 KSHV LANA (aa 934–1162; NCBI Protein accession no. AAC55944), EBV EBNA1<sub>DBD</sub> (aa 461–641; NCBI Protein accession no. P03211), RFHVMn LANA<sub>DBD</sub> (aa 849–1071; NCBI Protein accession no. ABH07414) and RRV LANA<sub>DBD</sub> (aa 251–448; NCBI Protein accession no. AAF60071) were binarily and multiply aligned using 3D-PSSM version 2.6.0 (<http://www.sbg.bio.ic.ac.uk/servers/3dpssm/index.html>), PRALINE (<http://www.ibi.vu.nl/programs/>; reviewed by Pirovano & Heringa, 2010) and T-Coffee version 7.71 (<http://www.tcoffee.org/>; Notredame *et al.*, 2000).

**Computational prediction of the LANA<sub>DBD</sub> multimer structure.**

The M-ZDOCK program (<http://zlab.bu.edu/m-zdock>) was used to predict putative LANA<sub>DBD</sub> dimer and tetramer complexes. M-ZDOCK is a specially developed algorithm for predicting the structure of multimers based on the structure of unbound (or partially bound) monomers (Pierce *et al.*, 2005). The predicted tetramer of LANA<sub>DBD</sub> bound to LBS1/2 was modelled based on solved structures of EBNA1<sub>DBD</sub> (Bochkarev *et al.*, 1996).

**Plasmid constructs.** pcDNA 3.1 Flag-LANA<sub>DBD</sub> has been described previously (Garber *et al.*, 2001). Fragments containing LBS1 or LBS1/2 used as EMSA probes were produced by *XhoI/XbaI* digestion from pAG31 containing LBS1 and pAG43 containing LBS1/2, respectively, as described previously (Garber *et al.*, 2002).

pPuro/4TR, used for the short-term replication assay, was constructed by cloning four TR units from pCRII/4TR (Garber *et al.*, 2002; Hu *et al.*, 2002) into a pPur vector (BD Biosciences). PGL3/7TR, which contains seven TR units, was constructed from pAG9 (Garber *et al.*, 2001) and used as a reporter for LANA-dependent transcriptional repression assays.

**Alanine substitution mutagenesis.** A PCR-based QuikChange Site-directed Mutagenesis kit (Stratagene) was used to generate alanine substitution mutants in LANA<sub>DBD</sub>, as recommended by the manufacturer. Primers containing the desired alanine substitution were designed using the web-based program Primer X (<http://bioinformatics.org/primerx>) (see Supplementary Table S1, available in JGV Online). All constructs were confirmed by sequencing (Davis Sequencing Co.).

**Cell lines.** CV-1 cells, African green monkey fibroblasts, 293 cells, human embryonic kidney cells, were obtained from ATCC. Cell monolayers were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 5 U penicillin ml<sup>-1</sup> and 5 µg streptomycin ml<sup>-1</sup> (all from Mediatech) at 37 °C under a 5% CO<sub>2</sub> atmosphere.

**Expression of wild-type and mutant LANA<sub>DBD</sub> proteins with the MVA/T7 expression system.** Wild-type and mutant LANA<sub>DBD</sub> proteins were produced by using an MVA/T7 expression system (Moss *et al.*, 1990). Briefly, highly confluent CV-1 cells in 10 cm plates were infected with MVA/T7 virus as described previously (Garber *et al.*, 2001; Moss *et al.*, 1990) and transfected at 3 h post-infection using a slightly modified calcium phosphate methods (Sambrook & Russell, 2001). Cells were harvested at 36–40 h post-transfection. His-tagged wt or mutant LANA<sub>DBD</sub> proteins were purified using Ni<sup>2+</sup>/Tris(carboxymethyl)ethylenediamine columns (Active Motif). Protein concentrations were determined by BCA assays (Bio-Rad) and protein expression levels were determined by Western blot analysis using anti-Flag M2 antibody (Sigma-Aldrich).

**EMSA.** For probe labelling, fragments containing LBS1 or LBS1/2 were labelled using T4 polynucleotide kinase (NEB) in the presence of [ $\gamma$ -<sup>32</sup>P]ATP (Amersham Biosciences) following the manufacturer's instructions. EMSAs were performed as described previously (Garber *et al.*, 2001). Captured protein–DNA complex signals on the phosphor screen were analysed using a Typhoon 9410 phosphor-imager system (Amersham Bioscience).

**Co-immunoprecipitation.** Plasmids expressing wt and mutant Flag-tagged LANA<sub>DBD</sub> proteins and a plasmid expressing wt HA-tagged LANA<sub>DBD</sub> were co-transfected to evaluate dimer formation. Co-transfected cells were harvested at 36–40 h post-transfection, lysed in lysis buffer and pre-cleared by centrifugation. Lysates were co-immunoprecipitated with anti-Flag M2 beads. LANA<sub>DBD</sub> complexes were separated by SDS-PAGE and the amount of HA-tagged wt LANA<sub>DBD</sub> was detected and quantified by Western blotting using anti-HA antibody. Dimerization activity for each mutant was normalized based on the expression level of Flag-tagged wt or mutant LANA<sub>DBD</sub> proteins.

**Short-term DNA replication assays.** Co-transfection of 3 × 10<sup>6</sup> 293 cells with 8 µg pPuro/4TR plasmid and 2 µg wt or mutant LANA<sub>DBD</sub> expression plasmids was carried out using TransIT-293 Transfection Reagent (Mirus). Transfection efficiency was monitored using

pcDNA3/LacZ. Short-term DNA replication assays were performed as described previously (Hu *et al.*, 2002). Captured signals on the phosphor screen were analysed using a Typhoon 9410 phosphor-imager system.

**Luciferase reporter assays.** For transcriptional repression assays, 20 ng pGL3/7TR luciferase plasmid as a reporter and 380 ng wt or mutant plasmid as an effector were co-transfected into 3 × 10<sup>5</sup> 293 cells using TransIT-293 Transfection Reagent. To monitor transfection efficiency, pMaxGFP plasmid was co-transfected with these plasmids and transfection efficiency was over 90%. Relative light units (RLUs) were measured at 48 h post-transfection. Protein concentrations were determined by BCA assay, and RLU values were normalized to the protein concentration. This was based on previous observations that LANA modulates a wide range of promoters (Renne *et al.*, 2001). Reporter gene activity values represented the mean of several independent transfections performed in triplicate (means ± SD).

## ACKNOWLEDGEMENTS

We thank Dr Robert McKenna and Dr David C. Bloom for helpful advice and critical reading of this manuscript. This work was supported by grants R01 CA88763 and R01 CA119917 from the NIH National Cancer Institute to R. R.

## REFERENCES

- Ballestas, M. E. & Kaye, K. M. (2001). Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mediates episome persistence through *cis*-acting terminal repeat (TR) sequence and specifically binds TR DNA. *J Virol* **75**, 3250–3258.
- Ballestas, M. E., Chatis, P. A. & Kaye, K. M. (1999). Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. *Science* **284**, 641–644.
- Barbera, A. J., Chodaparambil, J. V., Kelley-Clarke, B., Joukov, V., Walter, J. C., Luger, K. & Kaye, K. M. (2006). The nucleosomal surface as a docking station for Kaposi's sarcoma herpesvirus LANA. *Science* **311**, 856–861.
- Bates, P. A., Kelley, L. A., MacCallum, R. M. & Sternberg, M. J. (2001). Enhancement of protein modeling by human intervention in applying the automatic programs 3D-JIGSAW and 3D-PSSM. *Proteins* (Suppl. 5), 39–46.
- Bochkarev, A., Barwell, J. A., Pfuetzner, R. A., Furey, W., Jr, Edwards, A. M. & Frappier, L. (1995). Crystal structure of the DNA-binding domain of the Epstein–Barr virus origin-binding protein EBNA 1. *Cell* **83**, 39–46.
- Bochkarev, A., Barwell, J. A., Pfuetzner, R. A., Bochkareva, E., Frappier, L. & Edwards, A. M. (1996). Crystal structure of the DNA-binding domain of the Epstein–Barr virus origin-binding protein, EBNA1, bound to DNA. *Cell* **84**, 791–800.
- Burnside, K. L., Ryan, J. T., Bielefeldt-Ohmann, H., Bruce, A. G., Thouless, M. E., Tsai, C. & Rose, T. M. (2006). RFHVMn ORF73 is structurally related to the KSHV ORF73 latency-associated nuclear antigen (LANA) and is expressed in retroperitoneal fibromatosis (RF) tumor cells. *Virology* **354**, 103–115.
- Ceccarelli, D. F. & Frappier, L. (2000). Functional analyses of the EBNA1 origin DNA binding protein of Epstein–Barr virus. *J Virol* **74**, 4939–4948.
- Cesarman, E., Chang, Y., Moore, P. S., Said, J. W. & Knowles, D. M. (1995). Kaposi's sarcoma-associated herpesvirus-like DNA sequences

- in AIDS-related body-cavity-based lymphomas. *N Engl J Med* **332**, 1186–1191.
- Chang, Y., Cesarman, E., Pessin, M. S., Lee, F., Culpepper, J., Knowles, D. M. & Moore, P. S. (1994).** Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. *Science* **266**, 1865–1869.
- Cotter, M. A. & Robertson, E. S. (1999).** The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells. *Virology* **264**, 254–264.
- Cruikshank, J., Shire, K., Davidson, A. R., Edwards, A. M. & Frappier, L. (2000).** Two domains of the Epstein–Barr virus origin DNA-binding protein, EBNA1, orchestrate sequence-specific DNA binding. *J Biol Chem* **275**, 22273–22277.
- de Prat-Gay, G., Gaston, K. & Cicero, D. O. (2008).** The papillomavirus E2 DNA binding domain. *Front Biosci* **13**, 6006–6021.
- Fiser, A. & Sali, A. (2003).** ModLoop: automated modeling of loops in protein structures. *Bioinformatics* **19**, 2500–2501.
- Fujita, T., Ikeda, M., Kusano, S., Yamazaki, M., Ito, S., Obayashi, M. & Yanagi, K. (2001).** Amino acid substitution analyses of the DNA contact region, two amphipathic  $\alpha$ -helices and a recognition-helix-like helix outside the dimeric  $\beta$ -barrel of Epstein–Barr virus nuclear antigen 1. *Intervirology* **44**, 271–282.
- Gao, S. J., Kingsley, L., Li, M., Zheng, W., Parravicini, C., Ziegler, J., Newton, R., Rinaldo, C. R., Saah, A. & other authors (1996).** KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. *Nat Med* **2**, 925–928.
- Garber, A. C., Shu, M. A., Hu, J. & Renne, R. (2001).** DNA binding and modulation of gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. *J Virol* **75**, 7882–7892.
- Garber, A. C., Hu, J. & Renne, R. (2002).** Latency-associated nuclear antigen (LANA) cooperatively binds to two sites within the terminal repeat, and both sites contribute to the ability of LANA to suppress transcription and to facilitate DNA replication. *J Biol Chem* **277**, 27401–27411.
- Grossman, S. R. & Laimins, L. A. (1996).** EBNA1 and E2: a new paradigm for origin-binding proteins? *Trends Microbiol* **4**, 87–89.
- Grundhoff, A. & Ganem, D. (2003).** The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus permits replication of terminal repeat-containing plasmids. *J Virol* **77**, 2779–2783.
- Hantz, S., Couvreur, A., Champier, G., Trapes, L., Cotin, S., Denis, F., Bouaziz, S. & Alain, S. (2009).** Conserved domains and structure prediction of human cytomegalovirus UL27 protein. *Antivir Ther* **14**, 663–672.
- Hass, M., Lelke, M., Busch, C., Becker-Ziaja, B. & Gunther, S. (2008).** Mutational evidence for a structural model of the Lassa virus RNA polymerase domain and identification of two residues, Gly1394 and Asp1395, that are critical for transcription but not replication of the genome. *J Virol* **82**, 10207–10217.
- Havraneck, J. J., Duarte, C. M. & Baker, D. (2004).** A simple physical model for the prediction and design of protein–DNA interactions. *J Mol Biol* **344**, 59–70.
- Hegde, R. S., Grossman, S. R., Laimins, L. A. & Sigler, P. B. (1992).** Crystal structure at 1.7 Å of the bovine papillomavirus-1 E2 DNA-binding domain bound to its DNA target. *Nature* **359**, 505–512.
- Hirt, B. (1967).** Selective extraction of polyoma DNA from infected mouse cell cultures. *J Mol Biol* **26**, 365–369.
- Hu, J., Garber, A. C. & Renne, R. (2002).** The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus supports latent DNA replication in dividing cells. *J Virol* **76**, 11677–11687.
- Kedes, D. H., Operskalski, E., Busch, M., Kohn, R., Flood, J. & Ganem, D. (1996).** The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. *Nat Med* **2**, 918–924 (erratum: *Nat Med* **1996** **2**, 1041).
- Kelley-Clarke, B., Ballestas, M. E., Srinivasan, V., Barbera, A. J., Komatsu, T., Harris, T. A., Kazanjian, M. & Kaye, K. M. (2007).** Determination of Kaposi's sarcoma-associated herpesvirus C-terminal latency-associated nuclear antigen residues mediating chromosome association and DNA binding. *J Virol* **81**, 4348–4356.
- Liang, H., Petros, A. M., Meadows, R. P., Yoon, H. S., Egan, D. A., Walter, K., Holzman, T. F., Robins, T. & Fesik, S. W. (1996).** Solution structure of the DNA-binding domain of a human papillomavirus E2 protein: evidence for flexible DNA-binding regions. *Biochemistry* **35**, 2095–2103.
- Lieberman, P. M., Hu, J. & Renne, R. (2007).** Gammaherpesvirus maintenance and replication during latency. In *Human Herpesvirus: Biology, Therapy and Immunoprophylaxis*, pp. 379–402. Edited by A. Arvin, G. Campadelli-Fiume, E. Mocarski, P. S. Moore, B. Roizman, R. Whitley and K. Yamaniishi. New York: Cambridge University Press.
- Lim, C., Sohn, H., Lee, D., Gwack, Y. & Choe, J. (2002).** Functional dissection of latency-associated nuclear antigen 1 of Kaposi's sarcoma-associated herpesvirus involved in latent DNA replication and transcription of terminal repeats of the viral genome. *J Virol* **76**, 10320–10331.
- Moss, B., Elroy-Stein, O., Mizukami, T., Alexander, W. A. & Fuerst, T. R. (1990).** Product review. New mammalian expression vectors. *Nature* **348**, 91–92.
- Notredame, C., Higgins, D. G. & Heringa, J. (2000).** T-Coffee: a novel method for fast and accurate multiple sequence alignment. *J Mol Biol* **302**, 205–217.
- Pierce, B., Tong, W. & Weng, Z. (2005).** M-ZDOCK: a grid-based approach for Cn symmetric multimer docking. *Bioinformatics* **21**, 1472–1478.
- Pierce, B., Tong, W. & Weng, Z. (2007).** ZRANK: reranking protein docking predictions with an optimized energy function. *Proteins* **67**, 1078–1086.
- Pirovano, W. & Heringa, J. (2010).** Protein secondary structure prediction. *Methods Mol Biol* **609**, 327–348.
- Purta, E., van Vliet, F., Tricot, C., De Bie, L. G., Feder, M., Skowronek, K., Droogmans, L. & Bujnicki, J. M. (2005).** Sequence–structure–function relationships of a tRNA (m<sup>7</sup>G46) methyltransferase studied by homology modeling and site-directed mutagenesis. *Proteins* **59**, 482–488.
- Renne, R., Barry, C., Dittmer, D., Compitello, N., Brown, P. O. & Ganem, D. (2001).** Modulation of cellular and viral gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus. *J Virol* **75**, 458–468.
- Sambrook, J. & Russell, D. W. (eds) (2001).** *Molecular Cloning: a Laboratory Manual*, 3rd edn. New York: Cold Spring Harbor Laboratory Press.
- Schepers, A., Ritzi, M., Bousset, K., Kremmer, E., Yates, J. L., Harwood, J., Diffley, J. F. & Hammerschmidt, W. (2001).** Human origin recognition complex binds to the region of the latent origin of DNA replication of Epstein–Barr virus. *EMBO J* **20**, 4588–4602.
- Schwam, D. R., Luciano, R. L., Mahajan, S. S., Wong, L. & Wilson, A. C. (2000).** Carboxy terminus of human herpesvirus 8 latency-associated nuclear antigen mediates dimerization, transcriptional repression, and targeting to nuclear bodies. *J Virol* **74**, 8532–8540.
- Soulier, J., Grollet, L., Oksenhendler, E., Cacoub, P., Cazals-Hatem, D., Babinet, P., d'Agay, M. F., Clauvel, J. P., Raphael, M. & Degos, L. (1995).**

Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multi-centric Castleman's disease. *Blood* **86**, 1276–1280.

**Stedman, W., Deng, Z., Lu, F. & Lieberman, P. M. (2004).** ORC, MCM, and histone hyperacetylation at the Kaposi's sarcoma-associated herpesvirus latent replication origin. *J Virol* **78**, 12566–12575.

**Verma, S. C., Choudhuri, T., Kaul, R. & Robertson, E. S. (2006).** Latency-associated nuclear antigen (LANA) of Kaposi's sarcoma-associated herpesvirus interacts with origin recognition complexes at the LANA binding sequence within the terminal repeats. *J Virol* **80**, 2243–2256.

**Verma, S. C., Lan, K. & Robertson, E. (2007).** Structure and function of latency-associated nuclear antigen. *Curr Top Microbiol Immunol* **312**, 101–136.

**Wong, L. Y. & Wilson, A. C. (2005).** Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen induces a strong bend on binding to terminal repeat DNA. *J Virol* **79**, 13829–13836.

**You, J., Srinivasan, V., Denis, G. V., Harrington, W. J., Jr, Ballestas, M. E., Kaye, K. M. & Howley, P. M. (2006).** Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen interacts with bromodomain protein Brd4 on host mitotic chromosomes. *J Virol* **80**, 8909–8919.